Now, DEA also has to weigh in
on changes of scientific protocol, and that can really slow things down, says Vandrey of Johns Hopkins, who is collaborating
on a study there to compare the
analgesic effects of cannabis and the
opioid drug hydrocodone in healthy subjects.